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Neuropathic pain is a clinical manifestation of nerve injury difficult to treat even with potent analgesic compounds. Here, we used
different lines of geneticallymodifiedmice to clarify the role playedbyCB2 cannabinoid receptors in the regulationof the central immune
responses leading to the development of neuropathic pain. CB2 knock-out mice and wild-type littermates were exposed to sciatic nerve
injury, and both genotypes developed a similar hyperalgesia and allodynia in the ipsilateral paw. Most strikingly, knock-outs also
developed a contralateralmirror imagepain, associatedwith an enhancedmicroglial and astrocytic expression in the contralateral spinal
horn. In agreement, hyperalgesia, allodynia, and microglial and astrocytic activation induced by sciatic nerve injury were attenuated in
transgenicmice overexpressingCB2 receptors. These results demonstrate the crucial role ofCB2 cannabinoid receptor inmodulating glial
activation in response to nerve injury. The enhanced manifestations of neuropathic pain were replicated in irradiated wild-type mice
reconstituted with bone marrow cells from CB2 knock-outs, thus demonstrating the implication of the CB2 receptor expressed in hema-
topoietic cells in the development of neuropathic pain at the spinal cord.
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Introduction
The interest in themedical use of cannabinoid ligands has greatly
increased in the last few years. Two cannabinoid receptors, CB1
and CB2 (Matsuda et al., 1990; Munro et al., 1993), have been
extensively studied to clarify their involvement in several patho-
physiological situations in which cannabinoid ligands could be
potential therapeutic agents, including pain management. In-
deed, cannabis derivatives have been used for centuries as anal-
gesic compounds, and cannabinoid agonists have been reported
to be effective on several animalmodels of acute and chronic pain
(Pertwee, 2001). However, the psychoactive effects of these ago-
nists could represent a serious limitation for their clinical use.
CB1 receptors, mainly located in the CNS (Tsou et al., 1998),
seem to be selectively involved in cannabinoid psychoactive ef-
fects (Ledent et al., 1999; Zimmer et al., 1999). Interestingly, the
activation of CB1 receptors expressed in peripheral nociceptors
but not in the CNS attenuates neuropathic pain in rodents (Agar-
wal et al., 2007). The identification of CB2 receptors in glial cells
(Zhang et al., 2003; Beltramo et al., 2006) has opened new thera-
peutic approaches for these ligands. CB2 receptors have been also
proposed to be present in neurons (Van Sickle et al., 2005), al-
though this issue is still controversial. CB2 receptor activation
induces analgesic effects in several animal models (Beltramo et
al., 2006; Ibrahim et al., 2006; Bingham et al., 2007; Giblin et al.,
2007), and selective CB2 agonists could be potentially used as
analgesic drugs, thus circumventing psychoactive side effects of
CB1 agonists (Whiteside et al., 2007).
In the spinal cord, CB2 receptor expression was induced dur-
ing neuropathic pain produced by peripheral nerve injury in par-
allel with the simultaneous expression of activated microglia
(Zhang et al., 2003). Microglia seem to be involved in the devel-
opment of neuropathic pain through the release of several cyto-
kines, which are known to produce neuron sensitization in the
spinal cord (DeLeo and Yezierski, 2001; Clark et al., 2007). Inter-
estingly, CB2 receptor stimulation has been reported to attenuate
microglial activation (Ehrhart et al., 2005; Romero-Sandoval and
Eisenach, 2007) and CB2 agonists induce analgesic effects in neu-
ropathic painmodels (Ibrahim et al., 2003). Although these stud-
ies suggest a potential role for CB2 receptors in themodulation of
neuropathic pain, the mechanism underlying these analgesic ef-
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fects and the exact involvement of CB2 receptors in the develop-
ment of neuropathic pain has not been clarified yet. We have
therefore now used genetically modified mice lacking (CB2
/)
(Buckley et al., 2000; Ofek et al., 2006) or overexpressing CB2
cannabinoid receptors to evaluate the participation of these re-
ceptors in the behavioral and histological consequences of the
development of neuropathic pain after partial sciatic nerve in-
jury. Additional experiments using irradiated wild-type (WT)
(CB2
/) mice receiving bone marrow transplantation from
CB2
/ have been performed to identify the biological mecha-
nisms involved in the regulation of neuropathic pain responses
by CB2 receptors.
Materials andMethods
Animal experimental conditions. Animals were housed in groups of three
to five and had ad libitum access to water and food. The housing condi-
tions were maintained at 21 1°C and 55 10% relative humidity in a
controlled light/dark cycle (light on between 8:00 A.M. and 8:00 P.M.).
All experimental procedures and animal husbandry were conducted ac-
cording to standard ethical guidelines (European Community Guide-
lines on the Care and Use of Laboratory Animals 86/609/EEC) and ap-
proved by the local ethical committee (Comite´ Etico Experimental
Animal–InstitutoMunicipal de Asistencia Sanitaria/Universitat Pompeu
Fabra, Bezirksregierung Ko¨ln). All experiments were performed under
blind conditions.
CB2 knock-out mice.Male and female CB2 knock-outs (CB2
/) mice
andwild-type littermates (CB2
/) on aC57BL/6J congenic background
(Buckley et al., 2000), 3 months of age and weighing 23–29 g at the
beginning of the experiments, were used.
Plasmid constructs and generation of transgenicmice overexpressing CB2.
The open reading (ORF) of themurine CB2 receptor was isolated by PCR
amplification from mice brain mRNA, using primers which created a
XhoI restriction enzyme site adjacent to the translation start and stop
sites. The expression vector MoPrP.Xho (Watkins et al., 2003) was used
for the production of transgenic mice. This vector contains the murine
PrP promoter, exon 1, intron 1, exon 2, and 3 untranslated sequences.
The CB2 receptor ORF was cloned in exon 2 of MoPrP.Xho construct
(Watkins et al., 2003). The PrP-CB2 transgene was excised from the
plasmid vector with restriction endonuclease NotI leading to DNA frag-
ments of 12 kb. Transgenic founders were crossed with outbred CD-1
mice for seven generations. The presence of the transgene was deter-
mined by PCR using specific primers again exon 2 of PrP (5-CCAGC-
CTCCACCACCATGTGGC) and CB2 receptor (5-AGCCACCGTTG-
GAGCCGTTG).
Analysis of CB2mRNA expression by real-time PCR.Micewere killed by
cervical dislocation. Brains, and cervical and thoracic sections of the
spinal cord were removed rapidly, fresh-frozen, and stored immediately
at80°C until use. Brain sections were cut at 500 m at different levels
containing the regions of interest: thalamus and periaqueductal gray
(PAG). These sections were obtained according to Paxinos and Franklin
(2001), mounted onto slides, and stored at 80°C until use. Sections
were dissected following themethod described by Palkovits (1983). Total
RNA was extracted from brain punches and spinal cord sections using
Ultraspec RNA (Biotecx). After DNase digestion, the reverse transcrip-
tionwas performed following themanufacturer’s instructions of Epicen-
ter Technologies Corporation. Quantitative PCRwas performed in three
replicates using a Rotorgene 3000 Real Time Cycler (Corbett Research)
and SYBR Green (Invitrogen) as a double-stranded DNA-specific fluo-
rescent dye (Gutie´rrez-Ada´n et al., 2004). Primers for transgenic quanti-
fication were the same as described above. Primers for the quantification
of the expression of endogenous CB2 were 5-TCTGGAAAGCC-
CACCGGCATGTAG and 5-CAAGGCACAGCATGGAACAGAAGG.
The comparative CT method was used for quantification of expression
levels (Gutie´rrez-Ada´n et al., 2004). A GADPH cDNA was used as nor-
malization control to ensure constant GADPH levels in all samples re-
gardless of experimental conditions. One-way repeated-measures
ANOVA (followed by multiple pairwise comparisons using Student–
Newman–Keuls method) were used for the analysis of differences in
mRNA expression assayed by quantitative reverse transcription-PCR.
Generation of bone marrow chimeric mice. Bone marrow (BM) cells
were harvested by flushing tibias and femurs from 6- to 8-week-old
CB2
/ or CB2
/ male donor mice with PBS. Single-cell suspensions
were prepared by filtering BM cells through a 100 m cell strainer.
CD45.1 congenic male recipient mice were given lethal total body irra-
diation (900 rad), and 24 h later were intravenously reconstituted with
5  106 BM cells. The animals received intraperitoneally 150 mg/kg
amoxicillin and 15 mg/kg clavulanic in a volume of 0.1 ml/10 g for 10 d
starting on the day of transfer. After 8 weeks of engraftment, the effi-
ciency of the reconstitution was assessed by flow cytometric analysis of
peripheral blood lymphocytes (PBLs). All mice were bled from the tail
vein and PBLs were analyzed by flow cytometry (FACS Canto Flow Cy-
tometer; BD Biosciences; FlowJo analysis software; Tree Star) with
monoclonal antibodies against CD45.1 and CD45.2 (BD Biosciences) to
determine the degree of chimerism.Only BM-chimericmice that showed
93% reconstitution efficiency with donor cells were chosen for the
experiments. CB2
/ mice reconstituted with CB2
/ BM are referred
to as chimera-WT, and CB2
/ animals reconstituted with CB2
/ BM
are referred to as chimera-CB2.
Preparation of microglia. Brains and spinal cords were removed from
perfused mice, and single-cell suspensions were generated and filtered
through a 100 m cell strainer. Percoll gradients of 30/37/70% were
performed for fractionation of cells at 1000  g for 30 min, and brain
mononuclear cells were collected from the interface. Flow cytometry was
performed as described for PBL analysis of animals.
Behavioral experiments. Hyperalgesia to noxious thermal stimulus
(plantar test) and allodynia to cold (cold-plate test) andmechanical stim-
uli (von Frey stimulation model) were used as outcome measures of
neuropathic pain. In the plantar test, the mean paw withdrawal latencies
for the ipsilateral and contralateral hindpaws were determined from the
average of three separate trials, taken at 5 min intervals to prevent ther-
mal sensitization and behavioral disturbances using a commercially
available apparatus (Ugo Basile Biological Research Apparatus) (Har-
greaves et al., 1988). The von Frey filament stimulation experiments were
conducted with calibrated nylon filaments (North Coast Medical) (see
Figs. 1, 4) or with a Dynamic Aesthesiometer (Ugo Basile Biological
Research Apparatus) (see Fig. 6). The threshold of response was calcu-
lated by using the up–down Excel program generously provided by the
BasbaumLaboratory. Clear pawwithdrawal, shaking, or lickingwas con-
sidered to be a nociceptive-like response (Chaplan et al., 1994). In the
cold-plate test (Columbus Instruments), the number of elevations of
each hindpaw was recorded in the mice exposed to the cold plate (5 
0.5°C) during 5 min.
In a first experimental sequence, CB2
/ (16 males plus 16 females)
and CB2
/ (16 males plus 15 females) were used. In the second study,
transgenic mice overexpressing CB2 receptors (12males plus 12 females)
and CB2
/ (12 males plus 12 females) were used. Finally, CB2
/ (10
males), CB2
/ (10 males), chimera-CB2 (12 males), and chimera-WT
(10males)mice were evaluated.Mice were first habituated for 1 h to each
different experimental test once daily during 4 d. After the habituation
period, baseline responses were established during 2 consecutive days for
each paradigm in the following sequence: von Frey model, plantar test
(30 min later), and cold-plate test (15 min later). All the behavioral tests
were performed in the same group of animals. One day after baseline
measurements, sciatic nerve injury was induced. A partial ligation of the
sciatic nerve at midthigh level just proximal to the trifurcation was per-
formed with one thigh ligature using a 9-0 silk thread to induce neuro-
pathic pain, as described previously (Malmberg and Basbaum, 1998).
CB2
/ and CB2
/mice were tested in each paradigm on days 3, 6, 8,
10, and 15 after the surgical procedure using the same sequence as for
baseline responses. Data were compared each experimental day by using
a two-way ANOVA (surgery and genotype as between-group factors)
followed by corresponding one-way ANOVA when appropriate.
Immunohistochemistry. At the end of the behavioral experiment, three
to five mice per group were deeply anesthetized with ketamine/xylazine
(50/10 mg/kg) and then intracardially perfused with heparinized phos-
phate buffer (PB), followed by 4%paraformaldehyde. The lumbar region
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of the spinal cord was removed, postfixed in 4% paraformaldehyde for
2 h, and cryopreserved in 15% sucrose solution at 4°C. The section from
L2 to L6–S1 of the spinal cord was selected and then embedded in OCT,
sliced in 25msections on a cryostat, andmounted six sections permice
and two mice per slide in Star frost-coated slides.
The slides were incubated in polyclonal iba1 antibody (1:200; Wako
Chemicals) for microglia staining or polyclonal GFAP antibody (1:1000;
Dako) for astrocyte staining at 4°C overnight. The immunohistochemi-
cal assays were followed by incubation in the CY3 anti-rabbit secondary
antibody (1:500; Jackson Immunoresearch) for iba1 or GFAP for 1 h at
room temperature. After washing three times with 0.1 M PB, the slides
were mounted with Mowiol.
For the low-magnification images, the stained sections of the lumbar
dorsal horn were viewed at 10 objective and recorded with a Leica
DMR microscope equipped with digital camera Leica DFC 300 FX.
Confocal images were obtained using a Leica SP2 confocal micro-
scope, adapted to an inverted Leica DM IRBE microscope. Tissue sec-
tions of the lumbar dorsal horn were examined with a 40, 1.25 numer-
ical aperture oil-immersion Leica Plan Apochromatic objective. CY3was
excited with the 543 nm line of a green neon laser, and immunofluores-
cence images of three stained sections were taken for each animal. From
each section, images were always recorded of the ipsilateral and con-
tralateral dorsal horns. Nine to fifteen images were analyzed for each
experimental group with ImageJ software measuring the percentage of
stained occupied area. Data were compared by using one-way ANOVA
and least significant difference post hoc analysis.
CB2 staining. The spinal cords were removed and frozen on dry ice
without previous perfusion. They were sectioned in a cryostat at 20 m
thickness and mounted on glass slides. The tissues were fixed for 30 min
in 4% formaldehyde dissolved in 0.1 M PBS, pH 7.3. Next, the slides were
incubated for 15min in 0.3%H2O2, for 60min in 0.5%TritonX-100 and
for 2 h in 3% BSA. The slides were washed in PBS at least two times for 5
min between each incubation phase. The sections were labeled at 4°C for
20 h using a rabbit polyclonal CB2 primary antibody (1:1000; Abcam),
for microglia staining with iba1 polyclonal primary antibody (1:200;
Wako Chemicals), for astrocyte staining with polyclonal GFAP primary
antibody (1:1000; Dako), and for neuron staining with fluorescein-
conjugated Neu-N (1:500; Millipore Bioscience Research Reagents) pri-
mary antibody. The double staining for CB2 receptors and for microglia
or for astrocytes using secondary antibody from the same host was per-
formed using the method of To´th and Mezey (2007). Briefly, after label-
ing the CB2 receptors, the process was followed by using a Tyramide
Signal Amplification System (TSA Plus Fluorescence System;
PerkinElmer Life and Analytical Sciences). The slides were incubated for
30 min in streptavidin-HRP (1:200) dissolved in TNB buffer (0.1 M Tris,
pH 7.5, 0.15 M NaCl, 0.5% blocking reagent). The sections were washed
three times for 5 min and incubated in fluorophore tyramide (1:100 in
amplification reagent) for 6–9min. The slides were washed in PBS (three
times for 5 min), and fixed again for 15 min in 4% paraformaldehyde.
After washing in PBS (three times for 10 min), the assay was followed by
cooking the slides in the microwave in 10 mM citrate buffer, pH 6, for 5
min; after cooling (60–90 min), they were washed again. Next, the slides
were incubated in 0.5% Triton X-100 and in PBS containing 1% bovine
serum albumin and 10% goat serum for 60 min. The sections were la-
beled at 4°C for 20 husing rabbit polyclonal anti-GFAPprimary antibody
(1:1000; Dako) or rabbit polyclonal iba1 primary antibody (1:200;Wako
Chemicals). The assay was followed by incubation in Cy3-conjugated
donkey anti-rabbit IgG (1:250; Jackson Immunoresearch) secondary an-
tibody. The assays were followed by incubation with FITC-conjugated
donkey anti-rabbit (1:250; Jackson Immunoresearch) secondary anti-
body for microglia or for astrocytes at room temperature for 2 h. The
sections were washed in water and mounted in Vectashield Mounting
Medium (Vector Laboratories; H-1200). The sections were viewed under
fluorescence illumination (Zeiss Axioplanmicroscope). The images were
investigated using JVC (3-CCO) digital camera connected to the micro-
scope with the help of NIS-Elements software (Nikon).
Results
Themanifestations of neuropathic pain are enhanced in
CB2
/mice
Hyperalgesia to a noxious thermal stimulus (plantar test), and
allodynia to cold (cold-plate test) and mechanical stimuli (von
Frey stimulation model) were first used as outcome behavioral
measures of neuropathic pain. Baseline responses of CB2
/
mice andCB2
/ littermateswere similar in the three nociceptive
models, and shamoperation did not produce anymodification of
these nociceptive thresholds in both genotypes. Sciatic nerve in-
jury similarly enhanced thermal hyperalgesia and induced me-
chanical and thermal allodynia in the ipsilateral paw in both
CB2
/ and CB2
/mice (Fig. 1). Most strikingly, however, the
same degree of thermal hyperalgesia and mechanical allodynia
also developed in the contralateral pawofCB2
/mice, revealing
a mirror image of pain. This mirror image was not observed in
CB2
/mice (Fig. 1). A similar result was obtained in both sexes
of CB2
/ and CB2
/mice on the three nociceptive behavioral
measures (supplemental Fig. 1, available at www.jneurosci.org as
supplemental material). In agreement with previous reports
(Ibrahim et al., 2006), a trend to enhance basal nociceptive re-
sponse was observed in the plantar test in CB2
/mice, although
a significant effect ( p 0.05) was only revealed when analyzing
data from both genders together.
Figure 1. Development of neuropathic pain is enhanced inmale CB2
/ after sciatic nerve
injury when compared with CB2
/. A single tight ligature around one-third or one-half of
sciatic nerve wasmade to induce the neuropathic pain in CB2
/ (n	 16) and CB2
/mice
(n	 16). Mice were tested in the ipsilateral and contralateral paw for evaluating mechanical
allodynia (von Frey model; percentage of the basal CB2
/ sham-operated values) (A), ther-
mal hyperalgesia (plantar test; withdrawal latency in seconds) (B), and cold allodynia (cold-
plate test; number of pawelevations) (C) ondays 3, 6, 8, 10, and15 after surgery. Theblack stars
represent comparisonbetween sciatic nerve injury and sham-operated animals. Thewhite stars
represent comparison between genotypes. One star, p 0.05; two stars, p 0.01. Error bars
indicate SEM.
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Microglial cells are involved in the
enhancedmanifestations of neuropathic
pain in CB2
/mice
Glial cells are involved in neuropathic pain
and express CB2 receptors after nerve in-
jury (Ehrhart et al., 2005). Therefore, we
have evaluated glial response in the dorsal
horn of the lumbar spinal cord after sciatic
nerve injury or sham operation in CB2
/
and CB2
/mice to determine its possible
involvement in the increased neuropathic
pain sensitivity of CB2
/ animals. Sciatic
nerve injury induced a similar enhance-
ment of total microglial cell staining in the
dorsal and ventral ipsilateral horn of the
spinal cord in CB2
/ and CB2
/ mice.
Interestingly, a similar microglial reaction
was observed in the contralateral and ipsi-
lateral horns in CB2
/, but not in
CB2
/mice (Fig. 2). Similarly, an activa-
tion of microglia in the ipsilateral horns in
CB2
/ and CB2
/mice, and a stimula-
tion in the contralateral horns only in
CB2
/mice were observed. In agreement
with these findings, a significant increase
of the staining for iba1, a specific marker
for microglial cells, was observed in the ip-
silateral side after nerve injury in CB2
/
mice and in the ipsilateral and contralat-
eral side inCB2
/mice. This increasewas
attributable to an enhancement in the
number of microglial cells, which show
specific morphological changes (Fig. 2B).
Thus, typical restingmicroglia with a small
cell body and thin and large ramifications
were observed in sham-operated mice
(Fig. 2B). After nerve injury, these resting
microglia were present only in the con-
tralateral side of CB2
/mice. In contrast,
the ipsilateral side of CB2
/ mice and
both the ipsilateral and contralateral side
of CB2
/ mice contained microglia with
an activated phenotype. These cells have
bigger cell bodies, as well as thicker and
shorter ramifications (Fig. 2B). The same
result was also found in astrocytic re-
sponses, with a similar activation in the
ipsilateral horns in CB2
/ and CB2
/
mice, and a selective reaction in the con-
tralateral horns only in CB2
/mice (Fig.
2B). Thus, remarkably, the glial cell activa-
tion profile matched exactly the pattern of
nociceptive hypersensitivity. Because glial
activation and functional responses are in-
hibited by CB2 receptor stimulation
(Ehrhart et al., 2005; Romero-Sandoval
and Eisenach, 2007), these results suggest
that the suppression ofCB2 receptors had a
disinhibitory effect on the glial response
after sciatic nerve injury, thus leading to
exacerbated pain response in these ani-
mals, which was mainly revealed in the
contralateral side.
Figure 2. Enhanced glial activation in spinal cord of CB2
/ after sciatic nerve injury when compared with CB2
/mice. A,
Increase in iba-1 (microglia) (n	 5) and GFAP (astrocyte) (n	 5) staining in dorsal horn of lumbar spinal cord after sciatic nerve
injury in CB2
/ and in CB2
/mice.White bars, Ipsilateral paw; black bars, contralateral paw. Iba-1 and GFAP visualizedwith
CY3 anti-rabbit (red). Data are expressed as percentage of stained area. The black stars represent comparisons between sham-
operated and nerve injury between ipsilateral and contralateral paw. Thewhite stars represent comparisons between genotypes.
One star, p 0.05; two stars, p 0.01. Error bars indicate SEM. B, Representative confocal images of the immunostaining of
iba-1 and GFAP recorded with 40 objective in lumbar dorsal horn of CB2
/ and CB2
/. C, Representative low-
magnification images of iba-1 and GFAP immunostaining recordedwith 10 objective in the lumbar dorsal horn of sciatic nerve
injury CB2
/ and CB2
/mice.
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Neuropathic pain is attenuated in transgenic mice
overexpressing CB2 cannabinoid receptors
The manifestations of neuropathic pain induced by sciatic nerve
injury were also evaluated in transgenic mice overexpressing CB2
cannabinoid receptors. These transgenic mice were generated by
using a murine PrP promoter that is specifically expressed in
neurons and glial cells (Castilla et al., 2005). We obtained five
different transgenic lines. Three transgenic lines were selected by
evaluation of the transgenic CB2 receptor in different regions of
the brain (data not shown). One of these lines with high expres-
sion of transgenic CB2 receptor in the spinal cord was selected for
the present experiments. The expression of CB2 mRNAwas eval-
uated in several central structures related
to pain transmission in these mice by real-
timePCR. The expression ofCB2 receptors
wasmainly enhanced in transgenicmice at
the level of the spinal cord (205% at the
cervical level and 176% at the thoracic
level), although a clear enhancement was
also observed in supraspinal structures in-
volved in pain transmission, such as the
thalamus (95%) and the periaqueductal
gray matter (56%) (Fig. 3A). The different
expression observed in spinal cord, thala-
mus, and periaqueductal gray matter was
attributable to the murine PrP promoter
used in the transgene construct. To delin-
eate the cell types expressing CB2 recep-
tors, we performed an immunofluores-
cence analysis of spinal cord sections of
transgenicmice overexpressingCB2 recep-
tors.We found that CB2 receptors colocal-
ize with the microglia marker iba1 and
with the neuronal marker Neu-N, but not
with the astrocyte marker GFAP (Fig. 3B).
In agreement with the previous experi-
ment, baseline responses of transgenic
mice overexpressing CB2 receptors and
CB2
/ littermates were similar in the
three nociceptive models, and sham oper-
ation did not produce any modification in
the nociceptive thresholds. Thermal hy-
peralgesia and mechanical and thermal al-
lodynia induced by sciatic nerve injury in
the ipsilateral paw in CB2
/mice were all
strongly attenuated in transgenic mice
overexpressing CB2 receptors (Fig. 4). No
mirror image of pain was revealed in any
experimental group. A similar result was
observed in both genders of transgenic
mice overexpressing CB2 receptors on the
three nociceptive models (supplemental
Fig. 2, available at www.jneurosci.org as
supplemental material). Sciatic nerve in-
jury robustly enhanced the microglial re-
sponse in the ipsilateral horn of the spinal
cord inCB2
/mice, indicated by a signif-
icant increase of iba1 staining (Fig. 5A,B).
The enhanced iba1 staining was attribut-
able to an increased number of microglia,
with an activated phenotype. This re-
sponse was significantly attenuated in
transgenicmice overexpressingCB2 recep-
tors. Microglial staining was not significantly modified in the
contralateral horn in these groups of mice. Astrocytic staining
was also significantly enhanced in the ipsilateral horn of the spi-
nal cord in CB2
/ mice, but not in transgenic animals overex-
pressing CB2 receptors nor in the contralateral side in any exper-
imental group (Fig. 5A,B).
Sciatic nerve injury in CB2
//CB2
/ bone marrow
chimeric mice produced similar development of neuropathic
pain as in CB2
/mice
We have finally evaluated in vivo the involvement of the immune
system in the responses observed in CB2
/ mice. For this pur-
Figure 3. CB2 expression and colocalization inmale transgenicmice overexpressing CB2 receptors.A, Relative abundance of endoge-
nous and transgenic CB2 RNA in PAG, thalamus, cervical spinal cord, and thoracic spinal cord of transgenic mice was determined by
real-timePCRquantification.Afterbeinganalyzedusingthe
Ctmethod,datawerenormalizedtoGAPDHexpression.Thegroupwiththe
lowervaluewasassignedavalueof1.Thestarsrepresentdifferencesinrelativetranscriptabundancebetweenendogenousandtransgenic
CB2 receptor (one-way repeated-measures ANOVA). Error bars indicate SEM.B, Negative immunostaining for CB2 receptor in the lumbar
spinal cord of CB2
/ mice that serves as a control for CB2 staining in transgenic mice overexpressing CB2 receptors. C, Double-
fluorescenceimmunostainingforCB2receptor,GFAP(astrocyte),Neu-N(neuron),andiba-1(microglia) inlumbarspinalcordsectionsfrom
transgenicmice overexpressing CB2 receptors. First plot, Immunostaining for CB2 receptor (red; CY3 anti-rabbit) and for astrocytemarker
GFAP (green; FITC anti-rabbit). Secondplot, Same staining for CB2 receptor (red; CY3 anti-rabbit) and for neuron (fluorescein-conjugated
Neu-N). Third plot, Same staining for CB2 receptor (red; CY3 anti-rabbit) and formicroglialmarker iba-1 (green; FITC anti-rabbit).
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pose, we have replicated the phenotype of these knock-outs in
irradiated CB2
/ mice reconstituted with BM cells from
CB2
/mice (chimera-CB2). BM cells fromCB2
/ donor mice
expressing the surface antigen CD45.2 were intravenously in-
jected into lethally irradiated CD45.1 congenic recipients. After 8
weeks of engraftment, efficient reconstitution of recipient chi-
mericmice was verified by peripheral blood lymphocytes analysis
(Fig. 6A,B). Irradiated CB2
/ mice transplanted with CB2
/
BM cells served as controls (chimera-WT). Flow cytometry anal-
ysis of spinal cord tissues 14 d after surgery revealed a massive
recruitment of donor-derivedmicroglia. Baseline nociceptive re-
sponses were similar in all the experimental groups, and sham
operation did not modify these basal nociceptive thresholds (Fig.
6, Table 1). Sciatic nerve injury in BM-chimeric mice produced a
similar mechanical allodynia and thermal hyperalgesia in the ip-
silateral paw as was observed in CB2
/ and CB2
/ animals
(Fig. 6C, Table 1). However, mechanical and thermal allodynia
on the contralateral side was only present in the chimera-CB2
mice (constituted CB2
/ bone marrow cells) and in CB2
/
mice. Therefore, chimera-CB2 mice developed the same en-
hancedmanifestations of neuropathic pain as CB2
/ animals in
the previous experiment. In contrast, chimera-WT animals did
not show contralateral allodynia, and thus neuropathic pain of
these reconstituted animals did not differ from normal CB2
/
mice (Fig. 6C). Microglial cell activation induced by sciatic nerve
injury was evaluated by using immunofluorescence of iba1. A
similar enhancement was observed in the ipsilateral and con-
tralateral horn of the spinal cord in chimeric mice. A significant
increase of the iba1 staining of activated microglia was observed
in the ipsilateral and contralateral side after nerve injury in
chimera-CB2 mice. Astrocytic staining was also significantly en-
hanced in both ipsilateral and contralateral horns of the spinal
cord in chimeric CB2 mice (Fig. 7A,B).
Discussion
The present results reveal a crucial role of the CB2 cannabinoid
receptors in controlling the development of neuropathic pain
through an immunemechanism linked to glial activation.Hyper-
algesia and allodynia induced by sciatic nerve injury were en-
hanced in CB2
/mice, as revealed by a mirror image of pain in
the contralateral side. These behavioral manifestations of neuro-
pathic pain matched the changes induced in microglial and as-
trocyte activation. In agreement, a reducedmanifestation of neu-
ropathic pain after nerve injury was observed in transgenic mice
overexpressing CB2 receptors under the control of a PrP pro-
moter in the brain and the spinal cord. Expression of transgenic
CB2 receptors was pronounced in microglial cells and neurons,
but absent in astrocytes, in agreement with the literature (Van
Sickle et al., 2005; Romero-Sandoval et al., 2008). Decreased hy-
peralgesia, allodynia, and spinal glial activation in these trans-
genic mice could be related to the strong overexpression of CB2
receptors at the level of the spinal cord. However, these mice also
showed an enhanced expression of CB2 receptors in supraspinal
structures involved in pain transmission, such as the thalamus
and the periaqueductal gray matter, which could also participate
in the decreased manifestations of neuropathic pain. The oppo-
site phenotype revealed in transgenic mice overexpressing CB2
receptors and CB2
/ mice underlines the relevance of these
receptors in mediating the manifestations of neuropathic pain.
Similar baseline responses were obtained in the different lines of
genetically modified mice lacking or overexpressing CB2 recep-
tors, indicating the absence of nociceptive changes under physi-
ological conditions in these animals. These results suggest that
the activation of CB2 receptors could attenuate the manifesta-
tions of neuropathic pain at lower doses than those required to
induce antinociception.
The altered manifestations of neuropathic pain observed in
CB2
/mice and transgenic mice overexpressing CB2 receptors
suggest that endocannabinoids play an important role in the con-
trol of pain under these pathological conditions. In support of
this hypothesis, an enhancement in the levels of the two main
endocannabinoids, anandamide and 2-arachidonoyl-glycerol,
was revealed after sciatic nerve injury in the spinal cord and sev-
eral brain areas involved in pain, such as the periaqueductal gray
matter and the rostral ventral medulla (Petrosino et al., 2007).
The endocannabinoid levels were also enhanced after sciatic
nerve injury in the dorsal root ganglia (Mitrirattanakul et al.,
2006) and the section of the sciatic nerve proximal to the lesion
(Agarwal et al., 2007). These increased endocannabinoid levels
are likely related to enhanced biosynthesis or decreased catabo-
lism and transport because endocannabinoids are produced on
demand without any substantial storage (Di Marzo, 1998).
Therefore, endocannabinoids could produce a tonic activation of
CB2 receptors after sciatic nerve injury that would limit the pro-
gression and manifestations of neuropathic pain. In agreement,
both mechanical and thermal hyperalgesia produced after sciatic
nerve injury were attenuated by the administration of
N-arachidonoyl-serotonin, an inhibitor of fatty acid amide hy-
drolase, the enzyme responsible of the degradation of anandam-
Figure 4. Behavioral manifestations of neuropathic pain in male transgenic mice overex-
pressing CB2 receptors. Development of neuropathic pain inmale transgenicmice overexpress-
ing CB2 receptors (n	 12) and wild-type mice (n	 12). A single tight ligature around one-
third or one-half of sciatic nerve wasmade to induce the neuropathic pain. Mice were tested in
the ipsilateral and contralateral paw for evaluating mechanical allodynia (von Frey model;
percentage of the basal CB2
/ sham-operated values) (A), thermal hyperalgesia (plantar
test; withdrawal latency in seconds) (B), and cold allodynia (cold-plate test; number of paw
elevations) (C) on days 3, 6, 8, 10, and 15 after surgery. The black stars represent comparison
between sciatic nerve injury and sham-operated animals. Thewhite stars represent comparison
between genotypes. One star, p 0.05; two stars, p 0.01. Error bars indicate SEM.
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ide (Maione et al., 2007), which further support the role of endo-
cannabinoids in the control of neuropathic pain.
CB2 receptors are present in microglial cells (Romero-
Sandoval et al., 2008) and neurons (Van Sickle et al., 2005). How-
ever, the possible presence of CB2 receptors in neurons and its
possible functional role is still a controversial issue that requires
additional investigation. In the spinal cord, CB2 receptor expres-
sion is associatedwith the appearance of activatedmicroglial cells
after chronic pain produced by peripheral nerve injury (Zhang et
al., 2003). Glial activation has proinflammatory actions (Watkins
et al., 2003), and although it is not involved
in acute pain (Raghavendra et al., 2003), its
activation is required for the induction
and development of chronic pain states
(Raghavendra et al., 2003; Watkins et al.,
2003). Thus, microglia activation is in-
volved in the development of neuropathic
pain through the release of several cyto-
kines that are known to produce neuronal
sensitization in the spinal cord (DeLeo and
Yezierski, 2001; Clark et al., 2007) and ini-
tiate the neuroinflammatory process lead-
ing to the development of neuropathic
pain (Watkins et al., 2001). The chemical
modulators that activate microglial cells
are under the control of immune media-
tors, as well as neuromodulators released
by nearby neurons, such as prostaglandins
(Tanga et al., 2006). IFN- (interferon-)
is another mediator involved in microglia
activation that can induce an upregulation
of CB2 mRNA expression (Carlisle et al.,
2002). The complete neuroinflammatory
process leading to the progression of the
neuropathic pain requires the coactivation
of both microglia and astrocytes (Colburn
et al., 1999). Cytokines that are released by
the activated microglia, such as IL-1
(interleukin-1), can be responsible for
the subsequent activation of astrocytes,
which permits the consolidation of the
neuropathic pain state (John et al., 2004).
Interestingly, CB2 receptor stimulation
has been reported to attenuate microglial
activation (Ehrhart et al., 2005; Romero-
Sandoval and Eisenach, 2007) and the re-
lease of cytokines by the activated micro-
glia (Puffenbarger et al., 2000; Klegeris et
al., 2003; Sheng et al., 2005). In agreement,
CB2 agonists produce analgesic effects
(Ibrahim et al., 2005; Beltramo et al., 2006)
(for review, see Guindon and Hohmann,
2008) and reduce activated microglia in
neuropathic pain models (Romero-
Sandoval et al., 2008).
CB2 receptors located on microglial
cells would play a crucial role in limiting
the spreading of this neuroinflammatory
process. Thus, the activity of CB2 receptors
in microglial cells would reduce its activa-
tion during the development of neuro-
pathic pain and the consequent release of
proinflammatory cytokines. In the ab-
sence of CB2 receptors, a more widespread activation of micro-
glial cells occurs after sciatic nerve injury, which would lead to an
enhancement in the manifestations of neuropathic pain and to
the presence of a mirror image of pain in the contralateral side.
An alteration of the central immune responses after nerve
injury could be responsible for the enhanced manifestations of
the neuropathic pain in CB2
/mice. This hypothesis was dem-
onstrated by replicating the enhanced behavioral and histological
manifestations of neuropathic pain observed in CB2
/mice in
irradiated CB2
/ mice transplanted with bone marrow cells
Figure 5. Expression of glial activation in spinal cord of CB2
/ and transgenic mice overexpressing CB2 receptors. A, The
increase of microglia and astrocytic response in dorsal horn of lumbar spinal cord after sciatic nerve injury is only observed in
CB2
/mice. Iba-1 staining (microglia) (n	4per group) andGFAP staining (astrocytes) (n	4per group)were visualizedwith
CY3 anti-rabbit (red). Ipsilateral dorsal horns were represented with white bars, and contralateral dorsal horns were represented
with black bars. Data are expressed as percentage of stained area. Error bars indicate SEM. The black stars represent comparisons
between sham-operated and nerve injury or between ipsilateral and contralateral paw. The white stars represent comparisons
between genotypes. One star, p 0.05; two stars, p 0.01. B, Representative confocal images of the immunostaining of iba-1
(microglia) and GFAP (astrocyte) in lumbar dorsal horn of CB2
/ and transgenic mice overexpressing CB2 receptors recorded
with the 40 objective.
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fromCB2
/. These CB2
/BMchimeric
mice showed enhanced manifestations of
neuropathic pain as revealed by allodynia,
hyperalgesia, and astrocytic andmicroglial
cell activation in the contralateral side of
the spinal cord after sciatic nerve injury. By
generating bone marrow-chimeric mice,
we present evidence that newly recruited
monocytes from the bonemarrow of CB2-
deficient mice participate in the reconsti-
tution of spinal cord microglia after pe-
ripheral nerve injury.
Recently, it has been demonstrated that
bone marrow-derived cells that are re-
cruited to the spinal cord are implicated in
the development of neuropathic pain. In
particular, CCR2 expression in either res-
ident microglia or bone marrow-derived
macrophages may be sufficient for the de-
velopment of mechanical allodynia in a
murine neuropathic painmodel (Zhang et
al., 2007). Subsequent to nerve injury, gra-
dients formed by chemokine ligand 2
(CCL2) and CCL3 orchestrate the recruit-
ment and activation of resident and
monocyte-derived microglia via signaling
through their respective receptors CCR2,
CCR1, and CCR5 (Scholz and Woolf,
2007). CB2 cannabinoid receptor activity
may critically influence the induction of
CCR2 expression by monocytes and thus
inhibit their chemotaxis (Steffens et al.,
2005). Moreover, endocannabinoids were
found to abolish microglia activation by
inhibiting NO (nitric oxide) release
through amechanism linked to theMAPK
(mitogen-activated protein kinase) path-
way (Eljaschewitsch et al., 2006). There-
fore, our findings demonstrate a crucial
role of the immune response mediated by
microglia in the development of increased
neuropathic pain sensitivity in the CB2
/
animals. A direct action on peripheral CB2
receptors located in primary afferent neu-
rons (Wotherspoon et al., 2005; Beltramo
et al., 2006) and in keratinocytes involved
in the release of -endorphins (Ibrahim et
al., 2005) has been reported to be involved
in the analgesic responses of CB2 agonist.
However, these peripheral effects of CB2
receptors do not seem to be involved in the
enhanced manifestations of neuropathic
pain observed in the present study in CB2
knock-out mice.
Mice genetically modified either by in-
creasing or eliminating specific gene may
be limited by the fact that this genetic
changemay be affecting not only the target
gene but also other biological compo-
nents, perhaps participating in the effects
evaluated in these genetic models. There-
fore, pharmacological studies using selec-
tive ligands of CB2 receptors would be use-
Figure 6. Reconstitution efficiency of BM chimeric mice and behavioral manifestations of neuropathic pain after transplanta-
tion of BMcells lacking CB2 receptors in irradiated CB2
/mice.A, Lethally irradiated recipientmice (CD45.1)were reconstituted
with BM from CB2
/ (left) or WT (right) animals expressing the congenic marker CD45.2. Flow cytometry of peripheral blood
lymphocytes of BM chimericmicewas performed 8weeks later by stainingwith anti-CD45.1 and -CD45.2 antibodies. Frequencies
of CD45.2 donor-derived and CD45.1 recipient-derived cells are indicated in each quadrant. B, Presence of CB2-derived microglia
in the spinal cord of BM-chimeric mice 14 d after surgery. Representative flow cytometry demonstrating CD45.2CD11b cells
in the spinal cordof CB2
/ (CD45.2) controlmice (left) and lethally irradiatedCD45.1 congenic recipients after engraftmentwith
CB2
/ BM cells (chimera-CB2) (right). CD11b
 cells in the spinal cord of CD45.1 control mice (middle) are negative for the
congenicmarker CD45.2. Representativedotblots are shown.C, The followinggroupswere studied: CB2
/andCB2
/ control
animals, chimera-CB2 (CB2
/mice receiving bonemarrow from CB2
/ animals), and chimera-WT (CB2
/mice receiving
bonemarrow fromCB2
/mice). Development of neuropathic pain in CB2
/ (n	 10), CB2
/ (n	 10), chimera-WT (n	
8), and chimera-CB2 (n	 12). Mechanical allodynia after partial sciatic nerve ligation was tested in the ipsilateral and contralat-
eral paws onday 3, 6, 8, 10, and 15 after the surgery. Thewithdrawal thresholds are presented as percentage of the basal CB2
/
values. Error bars indicate SEM. The black stars represent comparison between sciatic nerve injury and sham-operated animals.
The white stars represent comparison between genotypes. One star, p 0.05; two stars, p 0.01.
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ful to confirm the relevance of the present results. Nevertheless,
these geneticmanipulations have been considered a key approach
to the identification of alterations associated to different patho-
logical conditions and to the discovering of new potential thera-
peutic targets in a variety of neuropsychiatric disorders. In this
study, the use of different lines of genetically modified mice and
the according results obtained in all these lines further support
the relevance of the findings.
Our findings reveal a crucial role of the CB2 receptor in the
modulation of the immune response of the nervous system dur-
ing neuropathic pain. In contrast, the genetic disruption of the
CB1 receptor had no major consequences on the development of
neuropathic pain (Castan˜e´ et al., 2006) despite the high expres-
sion of these receptors in the CNS (Tsou et al., 1998). Only CB1
receptors expressed in peripheral nociceptors but not in the CNS
seem to be involved in the manifestations of neuropathic pain
(Agarwal et al., 2007). The selective involvement of CB2 receptors
and the low expression in neurons (Van Sickle et al., 2005) fur-
ther emphasize the relevance of these receptors in the central
adaptive mechanisms leading to neuropathic pain. Therefore,
CB2 cannabinoid agonists could represent a new group of phar-
macological agents for the treatment of neuropathic pain devoid
of any psychoactive side effects.
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